The companies aim to develop microbiome diagnostic assays for colon cancer and other gastrointestinal diseases including irritable bowel syndrome.
Researchers found relevant non-coding mutations in colorectal cancer cell lines by systematically profiling chromosome interactions at promoter fragments.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The company will work with researchers at UCSD's Moores Cancer Center on two studies of patients with breast, lung, and colon cancers.
The company will work with medical faculties of the universities of Greifswald and Rostock to develop Dx tools for personalized, immune-based treatments.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
A multi-region analysis of colorectal cancers suggests samples from opposite sides of a tumor can help trace early, invasiveness-related tumor characteristics.
The company said test volume rose 87 percent to 186,000 during the quarter.
Prospective panel sequencing on colorectal cancer patients picked up Lynch syndrome with sensitivity and specificity that met or exceeded gene-by-gene tests.
The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.